+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05583617

Platform Study of Multiple Treatments Evaluating Safety and Effectiveness in Patients With Multiple Myeloma

Led by Hoffmann-La Roche · Updated on 2026-10-06

200

Participants Needed

16

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, effectiveness, and how the body processes pharmacokinetics several treatment combinations for participants with multiple myeloma, a type of blood cancer. This platform study allows new treatment substudies to be added as new options become available. Two specific substudies focus on different treatment combinations and participant groups based on their disease status and prior therapies. One substudy explores the combination of cevostamab and lenalidomide as maintenance therapy after stem cell transplant in patients with high-risk features who have responded to initial treatment. Cevostamab is given intravenously in a cycle of 28 days with an initial dose escalation phase, while lenalidomide is taken orally in 28-day cycles. Another substudy assesses the combination of cevostamab with iberdomide for participants with relapsed or refractory multiple myeloma who have undergone multiple prior treatments. Cevostamab is administered intravenously every 21 days, and iberdomide is taken orally on a 21-day cycle. Participants will be involved in scheduled dosing cycles with regular assessments and procedures. Researchers will monitor adverse events, response rates, progression-free survival, overall survival, and pharmacokinetic parameters up to approximately five years. Safety is closely observed, including management of potential side effects like cytokine release syndrome treated with tocilizumab if needed. The study includes multiple visits for dosing and evaluation, with long-term follow-up to assess outcomes and treatment effects.

CONDITIONS

Brief Title

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

Research Team

R

Reference Study ID Number: CO43923 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here